HTL Biotechnology joins the Choiseul Conquérants 2025 ranking
HTL Biotechnology is recognized for the second consecutive year among France’s most dynamic and innovative mid-sized companies.
Javené, October 9, 2023
HTL, pioneer in the development and production of innovative pharmaceutical-grade biopolymers, announces its new corporate social responsibility (CSR) strategy. It aims to accelerate the company’s commitment to its entire ecosystem and transform its activity into a positive and sustainable force.
The strategy includes 19 commitments, divided into three priority areas: responsibility to preserve the environment, exemplarity with employees, and citizenship with civil society.
HTL Biotechnology is recognized for the second consecutive year among France’s most dynamic and innovative mid-sized companies.
On October 28, 2025, HTL Biotechnology hosted its first-ever webinar, “Shaping the Future of Aesthetic Medicine with Premium Biopolymers,” a key initiative to strengthen our presence in Asia and promote the “Feel the Difference with HTL Inside” positioning among major players in aesthetic medicine.
This October, HTL Biotechnology turned pink to support breast cancer prevention.